New Aptar Pharma’s Nasal Spray for Treatment for Allergic Rhinitis Approved by US FDA

Glenmark’s Ryaltris™ nasal spray

Aptar Pharma, a worldwide leader in drug delivery systems, services, and active material science solutions, declared that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray.

It recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration (FDA) for treating symptoms of seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older. 

Metered Dose

Using Aptar Pharma’s creative VP3 nasal spray with a custom-designed smaller evaporation cap, Ryaltris™ is a metered, fixed-dose, aqueous suspension prescription combination drug product nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for the treatment of signs of seasonal allergic rhinitis, including nasal and ocular symptoms.

The pump for anti-allergic therapies Aptar Pharma’s VP3 technology medium has been the industry gold benchmark for multidose nasal sprays for over 40 years for anti-allergic treatments, for both innovator brands and generics for locally acting drug products. 

The technology complies with U.S. FDA requirements and other multinational regulatory authorities, with multiple customer reference products already commercialized worldwide.

The action to bring Ryaltris™ Nasal Spray to market was supported by a Combination Product Documentation package from Aptar Pharma’s Services offering, a comprehensive portfolio of stage-specific development packages. Aptar Pharma’s dedicated Regulatory Affairs professionals and analytical scientists help customers proactively address regulatory needs to accelerate approval.

“Glenmark’s constant focus is on delivering the right treatment options to the patients, using effective technology. Adapting Aptar Pharma’s innovative VP3 multidose device as the delivery system for our novel Ryaltris™ nasal spray is yet another effort in this regard,” said Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals Ltd. “This NDA approval by the U.S. FDA for a combination drug product using our VP3 multidose nasal pump further demonstrates Aptar Pharma’s ability to help our customers develop and launch novel treatments,” stated Gael Touya, President, Aptar Pharma. 

“Our nasal systems’ proven capabilities bring added value to our customers and further convenience for patients worldwide.” Already approved and marketed in several countries worldwide, Ryaltris™ will be sold and distributed in the United States by Hikma Specialty U.S.A., Inc. as part of its exclusive licensing agreement with Glenmark Specialty S.A. (Switzerland).

Imaginative tech Natural Branding: Laser marking on fruits and veggies

World’s first complete barrier aseptic carton without an Aluminium layer by SIG